BDRXBiodexa Pharmaceuticals Plc

Nasdaq midatechpharma.com


$ 1.03 $ 0.02 (2.48 %)    

Tuesday, 04-Jun-2024 13:50:41 EDT
QQQ $ 454.82 $ 2.44 (0.54 %)
DIA $ 398.57 $ 3.14 (0.82 %)
SPY $ 530.36 $ 2.21 (0.42 %)
TLT $ 91.26 $ 0.43 (0.47 %)
GLD $ 225.37 $ -0.78 (-0.36 %)
$ 1.07
$ 1.01
$ 1.03 x 600
$ 1.05 x 600
$ 1.01 - $ 1.05
$ 0.67 - $ 9.74
1,252,863
na
1.27B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biodexa-pharmaceuticals-highlights-phase-2-data-results-for-erapa

After the first six months, eRapa appeared to be safe and well-tolerated with a statistically significant 24% reduction (p=0.04...

 biodexa-pharmaceuticals-stock-is-tumbling-wednesday-whats-going-on

Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exer...

 biodexa-announces-7m-of-gross-proceeds-from-warrant-exercises-and-an-agreement-between-the-company-and-several-accredited-investors-to-exercise-certain-existing-series-e-warrants-and-series-f-warrants-to-purchase-up-to-an-aggregate-of-4358322-adss

Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesProceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...

 whats-going-on-with-biodexa-pharmaceuticals-stock

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment ...

Core News & Articles
Market-Moving News for May 21st
05/21/2024 12:42:13

BDRX: 110% | Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatou...

 biodexa-pharmaceuticals-presents-phase-2-clinical-trial-results-of-its-newly-licensed-erapa-in-familial-adenomatous-polyposis-scheduled-for-presentation-at-the-2024-digestive-disease-week-annual-meeting-reports-overall-83-non-progression-rate-at-6-months

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Tria...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION